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osting by EAbstract Purpose: To ﬁnd correlation between the type of mutations observed and the severity of
the disease using multiple techniques like polymerase chain reactions (PCR), quantitative multiplex
PCR, sequencing and RNA analysis.
Methods: Prospective, observational study. Patients who had been screened for mutations in the
RB1 gene were included in the study. Patient details including demographic data; age and sex, lat-
erality, international classiﬁcation of intraocular retinoblastoma (ICIOR) staging, modality of man-
agement, histopathology high risk factors if the eyes were enucleated and metastasis rate were
assessed.
Results: Seventy four patients were studied. Fifty three patients had bilateral and 21 unilateral dis-
ease. Complete genetic data was analyzed for 74 patients and complete clinical correlation was
established for all the 49 patients with mutations. Of the total mutations identiﬁed, 11/49
(22.4%) of patients had large deletions, 12/49 (24.5%) had small deletions or insertions, 14/49
(28.6%) had nonsense mutations, 7/49 (14.3%) had splice mutations and 5/49 (10.2%) of patients30612299.
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120 M.J. Ali et al.had missense mutations. Four cases were familial. Group E ICIOR stage at presentation was noted
in 40% of patients with large deletions, 33% with small deletions whereas 38.5% with splice muta-
tions and 44.4% of patients with missense mutations presented with Group B ICIOR. Twenty ﬁve
percentages of eyes with large deletions had high risk features on histopathology and one patient
among these developed metastasis.
Conclusion: Current laboratory testing of RB1 mutations may be feasible in determining the sever-
ity of the disease and patient counseling. The study provides a starting point for looking at corre-
lations.
ª 2010 King Saud University. All rights reserved.1. Introduction
Retinoblastoma (Rb) is the most common intraocular malig-
nancy in children, with a reported incidence ranging from 1
in 15,000 to 1 in 18,000 live births (Bishop and Madsen,
1975). It is second only to uveal melanoma in the frequency
of occurrence of malignant intraocular tumors. There is no ra-
cial or gender predisposition in the incidence of retinoblas-
toma. Retinoblastoma is bilateral in about 25–35% of cases
(Shields and Shields, 1992). The average age at diagnosis is
18 months, unilateral cases being diagnosed at around 24
months and bilateral cases before 12 months (Shields and
Shields, 1992).
Retinoblastoma (Rb) is brought about by biallelic inactiva-
tion of the human retinoblastoma susceptibility gene, RB1
(GenBank accession number L11910), located on chromosome
13q14 that codes for the RB protein. The cytogenetic deletions
examined in retinoblastomas have assigned the genetic locus of
the disease to q14 of chromosome 13 linked with the polymor-
phic marker gene enzyme esterase D (Friend et al., 1986). A
successful labeling of normal and tumor cells with homozy-
gous RB1 gene deletion in the human tumors, showed that
most RB1 deﬁcient tumor cells resemble cone photoreceptors,
suggesting that cone photoreceptors is the cell of origin (Xu
et al., 2009).
Retinoblastoma arises due to two genetic events involving
both the alleles of RB1 and occurs in two forms, the hereditary
and non-hereditary. Mutation of both the alleles of RB1 is re-
quired for tumor initiation. In case of hereditary transmission
of the disease, one allele is mutated in the germline and the
other mutation occurs somatically in the developing retina.
In non-hereditary disease, mutations of both the alleles so-
matic (Knudson, 1971; Mairal et al., 2000; Corson and Gallie,
2007). The RB1 gene shows a high degree of mutational heter-
ogeneity in retinoblastoma with over 900 mutations reported
till date (Valverde et al., 2005). Approaches using multiple
techniques including quantitative multiplex PCR and sequenc-
ing (Richter et al., 2003), or DHPLC (denaturing high-perfor-
mance liquid chromatography) along with quantitative
multiplex PCR for short ﬂuorescent fragments (QMPSF) Hou-
dayer et al., 2004 could achieve detection rate of 80–89%
(Richter et al., 2003; Houdayer et al., 2004). Precise identiﬁca-
tion of the RB1 gene mutation could help in enhancing the
clinical management of the relatives at risk (Gallie et al.,
1995). Genetic testing of retinoblastoma is being employed
to screen for and detect carriers of RB1 mutations among rel-
atives of affected individuals and for prenatal testing (Gallie
et al., 1999). This in turn can facilitate prompt management
of the disease and better visual outcome in affected children
(Gallie et al., 1999).Our group ﬁrst developed and published a combinatorial
approach for detection of RB1 mutations (Parsam et al.,
2009) and in the present study the authors attempted to corre-
late clinical features of the disease with RB1 mutations in 49
patients with known mutations.
2. Materials and methods
2.1. Study: prospective, observational
2.1.1. Technique
Mutational analysis of RB1 was carried out to detect different
types of mutations as previously described (Parsam et al.,
2009). Once our group had the genetic data, authors then cor-
related the different types of mutations with patient details like
demographic data; age and sex, laterality, international classi-
ﬁcation of intraocular retinoblastoma (ICIOR) staging,
modality of management, high risk factors if the eyes were
enucleated and metastasis rates. The following histopatholo-
gical entities were taken as high risk features: (Honavar
et al., 2002) anterior chamber seeding, iris inﬁltration, ciliary
body inﬁltration, massive choroidal inﬁltration, invasion of
optic nerve lamina cribrosa, retrolaminar optic nerve invasion,
invasion of optic nerve transection, scleral inﬁltration and
extrascleral extension.
3. Results
Seventy four patients were studied. Fifty three patients had
bilateral and 21 unilateral retinoblastoma. By combining the
three different approaches as elucidated in the techniques
above, mutations were detected in 49 patients (44 bilateral
and ﬁve unilateral) (Parsam et al., 2009). Complete genetic
data was analyzed for 74 patients and complete clinical corre-
lation was established for all the 49 patients with mutations.
Since the study is about the clinical correlation among patients
of retinoblastoma where mutations were identiﬁed, all the re-
sults would restrict to these 49 patients. There were 28 males
(57%) and 21 females (43%) among the study subjects. The
mean age was 17.2 months (range 3–38 months). Of the total
mutations identiﬁed, 11/49 (22.4%) of patients had large dele-
tions, 12/49 (24.5%) had small deletions or insertions, 14/49
(28.6%) had nonsense mutations, 7/49 (14.3%) had splice
mutations and 5/49 (10.2%) of patients had missense muta-
tions. Four cases were familial. 23/49 (46.94%) of the muta-
tions identiﬁed were not reported earlier to the best of our
knowledge and these were novel mutations identiﬁed in our
study (Parsam et al., 2009). The clinical details among each
class are as follows.
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Eleven of the 49 patients had large deletions accounting for
22.4% of all the mutations. There were six male and ﬁve fe-
male patients. 9/11 (81.8%) patients had bilateral retinoblas-
toma whereas 2/11 (18.2%) had unilateral retinoblastoma at
presentation. Of the 20 eyes that were studied in this group,
eight (40%) presented with Group E ICIOR followed by
groups B, D and C ICIOR. Two of the 20 (10%) presented
with extra ocular extension and one eye had presented after
enucleation elsewhere. Seven (35%) eyes were enucleated.
The other modalities of management in this group included
chemoreduction and focal therapy. Focal therapy here in-
cluded cryotherapy and transpupillary thermotherapy. Plaque
brachytherapy was evaluated separately. External beam radio-
therapy (EBRT) was given as a part of multimodal approach
for the extra ocular retinoblastomas. Five of the 20 eyes
(25%) had high risk histopathological features and these pa-
tients underwent adjuvant chemotherapy. One patient with ex-
tra ocular extension presented with metastasis and was
subjected for palliative treatment (Table 1).
3.2. Small deletions
Twelve of the 49 patients had small deletions accounting for
24.5% of all the mutations. There were eight male and four fe-
male patients. All these 12 patients had bilateral retinoblas-
toma at presentation. Of the 24 eyes that were studied in
this group, eight (33.3%) presented with Group E ICIOR fol-
lowed by groups B, D and C ICIOR. Two (8.3%) presented
with extra ocular extension and one eye had presented after
enucleation elsewhere. Eight (34%) eyes were enucleated.
The other modalities of management in this group included
chemoreduction, focal therapy and plaque brachytherapy.
External beam radiotherapy (EBRT) was given as a part of
multimodal approach for the extra ocular retinoblastoma.
Two (8.3%) of the eyes had high risk histopathological fea-Table 1 Clinical proﬁle of retinoblastoma patients with large RB1
No. of patients Sex No. of eyes Laterality Stage-eyes
Large deletions
11 6 M
5 F
20 Unilateral-2
patients
Bilateral-9
patients
B-4
C-2
D-3
E-8 (40%)
Extra ocular extensio
Enucleation else-1
Table 2 Clinical proﬁle of retinoblastoma patients with small RB1
No. of patients Sex No. of eyes Laterality Stage-eyes
Small deletions
12 8 M
4 F
24 All bilateral
RB patients
B-5
C-2
D-5
E-8 (33%)
Extra ocular extensi
Enucleation else whtures and these patients underwent adjuvant chemotherapy
(Table 2).
3.3. Nonsense mutations
Fourteen of the 49 patients had nonsense mutations account-
ing for 28.6% of all the mutations. There were six male and
eight female patients. Thirteen of the 14 patients (92.8%)
had bilateral retinoblastoma whereas the remaining one
(7.2%) patient had unilateral retinoblastoma at presentation.
Of the 27 eyes that were studied in this group, nine (33.3%)
presented with Group B ICIOR followed by groups C, E
and D ICIOR. Six (22.2%) eyes were enucleated. The other
modalities of management in this group included chemoreduc-
tion, focal therapy and plaque brachytherapy. Two (7.4%) of
the eyes had high risk histopathological features and these pa-
tients underwent adjuvant chemotherapy (Table 3).
3.4. Splice mutation
Seven of the 49 patients had splice mutations accounting for
14.3% of all the mutations. There were ﬁve male and two fe-
male patients. Six out of seven (85.7%) patients had bilateral
retinoblastoma whereas one (14.3%) had unilateral retinoblas-
toma at presentation. Of the 13 eyes that were studied in this
group, ﬁve (38.5%) presented with Group B ICIOR followed
by groups C, D and E ICIOR. Two (15.4%) eyes were enucle-
ated. The other modalities of management in this group in-
cluded chemoreduction, focal therapy and plaque
brachytherapy. Two (15.4%) of the eyes had high risk histopa-
thological features and these patients underwent adjuvant che-
motherapy (Table 4).
3.5. Missense mutation
Five of the 49 patients had nonsense mutations accounting for
10.2% of all the mutations. There were three male and twodeletions.
High risk features
(HRF)
Metastasis Management
n-2
5 1 Enucleation-7 (35%)
Chemoreduction-9
External beam radiotherapy-2
Focal therapy-5
Pallative therapy-1
Adjuvant chemotherapy-5
deletions.
High risk
features (HRF)
Metastasis Management
on-2
ere-1
2 Nil Enucleation-8 (34%)
Chemoreduction-11
External beam radiotherapy-2
Focal therapy-11
Pallative therapy-0
Adjuvant chemotherapy-5
Table 5 Clinical proﬁle of retinoblastoma patients with RB1 missense mutations.
No. of patients Sex No. of eyes Laterality Stage-eyes High risk
features (HRF)
Metastasis Management
Missense mutations
5 3 M
2 F
9 Unilateral patients-1
Bilateral patients-4
B-4 (44.5%)
C-1
D-2
E-2
1 Nil Enucleation-2 (22%)
Chemoreduction-3
External beam radiotherapy-0
Focal therapy-4
Adjuvant chemotherapy-2
Table 3 Clinical proﬁle of retinoblastoma patients with RB1 nonsense mutations.
No. of
patients
Sex No. of
eyes
Laterality Stage-eyes High risk features
(HRF)
Metastasis Management
Nonsense mutations
14 6 M
8 F
27 Unilateral patients-1
Bilateral patients-13
B-9 (33.3%)
C-6
D-4
E-6
Phthisis bulbi-1
Enucleation else where-1
2 Nil Enucleation-6 (22%)
Chemoreduction-14
External beam radiotherapy-0
Focal therapy-9
Plaque brachytherapy-1
Adjuvant chemotherapy-2
Table 4 Clinical proﬁle of retinoblastoma patients with RB1 splice mutations.
No. of patients Sex No. of eyes Laterality Stage-eyes High risk
features (HRF)
Metastasis Management
Splice mutations
7 5 M
2 F
13 Unilateral patients-1
Bilateral patients-6
B-5 (38.5%)
C-3
D-3
E-2
2 Nil Enucleation-2 (15.4%)
Chemoreduction-6
External beam radiotherapy-0
Focal therapy-6
Plaque brachytherapy-1
Adjuvant chemotherapy-2
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retinoblastoma whereas the remaining one (20%) had unilate-
ral retinoblastoma at presentation. Of the nine eyes that were
studied in this group, four (44.4%) presented with Group B
ICIOR followed by groups D, E and C ICIOR. Two (22%)
eyes were enucleated. The other modalities of management in
this group included chemoreduction and focal therapy. One
(11.1%) of the eyes had high risk histopathological features
and this patient underwent adjuvant chemotherapy (Table 5).
4. Discussion
In the present study a practical correlation between clinico-
pathological features of retinoblastoma with genetic muta-
tional status was attempted. The caveat in such studies is that
several different categories of mutation such as deletions or
insertions of different sizes, and nonsense mutations have the
same impact at the protein level. Essentially, the protein would
be truncated in case of all frame-shifting and nonsense muta-
tions, and so would be grossly defective or non-functional or
would have undergone degradation either at the mRNA or
protein level.Alonso et al. (2001) studied the spectrum of germ line RB1
mutations in a Spanish population and tried to bring out the
phenotypic and molecular implications of these mutations.
They found 29 mutations in 49 hereditary retinoblastoma pa-
tients, most of them (62%) not reported earlier. Sixty nine per-
centages of these were nonsense mutations and the remainder
splice mutations. Splice mutations were associated with de-
layed onset at presentation (32 months on average) whereas
nonsense mutations had early onset (8.7 months on average).
In comparison our study showed that 23 (46.94%) of the
mutations identiﬁed were not reported earlier to the best of
our knowledge, however early onset retinoblastomas in our
study were seen more with large deletions (mean age 13.64
months, range 3–22 months) and nonsense mutations (mean
age 14.43 months, range 5–26 months).
Taylor et al. (2006) were the ﬁrst to study genotype–pheno-
type correlations in hereditary familial retinoblastoma. This
was the ﬁrst large scale study of familial retinoblastoma with
high level of homogeneity in the clinical and genetic analysis
of patients and their relatives thereby allowing reliable intra-
familial genotype–phenotype correlations. They studied the
mutations and correlated them with demographic features,
RB1 gene mutations in retinoblastoma and its clinical correlation 123carrier and disease status and disease eye ratio. In comparison
since most of the patients (90% or more) presenting in our
clinic are sporadic cases, our series comprised sporadic and a
few familial cases. We took into consideration clinical manifes-
tations, stages at presentation and modalities of management.
Another factor in our study that limits interpretation is the
relatively small numbers of patients within each of the sub-
groups of patients having deletions, nonsense, splice and mis-
sense mutations. Group E ICIOR stage at presentation was
noted in 40% of patients with large deletions and 33% with
small deletions. However, 38.5% of patients with splice muta-
tions and 44.4% of patients with missense mutations presented
with Group B ICIOR. Twenty ﬁve percentages of eyes with
large deletions had high risk features on histopathology and
one patient among them developed metastasis. The tumor
stages could have also been inﬂuenced by delayed presentation,
however. More accurate data on age at onset, and comparison
of cases with early presentation would enhance correlations.
The current study despite its limitations, may be helpful in pro-
moting further larger studies and provides a starting point for
looking at correlations. We also feel the need for a larger more
uniform sample size with longer follow up to identify the ge-
netic factors that modify the relationship between genotype
and phenotype in retinoblastoma.Acknowledgement
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